HbA1c Targets for Controlled Type 2 Diabetes Mellitus

Introduction to HbA1c Targets

The National Institute for Health and Care Excellence (NICE) recommends targeting an HbA1c of <7% (53 mmol/mol) for most adults with controlled type 2 diabetes, with specific goals determined by treatment modality: 48 mmol/mol (6.5%) for those on lifestyle/diet alone or with a single non-hypoglycemic agent, and 53 mmol/mol (7.0%) for those on medications associated with hypoglycemia risk 1

For patients on lifestyle and diet alone, or with a single non-hypoglycemic drug, the target HbA1c is 48 mmol/mol (6.5%) 1
For patients on medications associated with hypoglycemia risk, the target HbA1c is 53 mmol/mol (7.0%) 1
For patients on dual or intensified therapy, the target HbA1c is 53 mmol/mol (7.0%) when HbA1c rises to 58 mmol/mol (7.5%) or higher despite single drug therapy 1

The American College of Physicians recommends an HbA1c target between 7-8% for most adults to balance benefits and harms 2
The HbA1c target can be relaxed to 7-8% or higher in older or frail adults, particularly those with limited functional status 1, 2
The HbA1c target can be relaxed to 7-8% or higher in patients with reduced life expectancy (<5-10 years), where long-term microvascular benefits are unlikely to be realized 1, 2
The HbA1c target can be relaxed to 7-8% or higher in patients with high risk of hypoglycemia consequences, significant comorbidities, or established advanced microvascular/macrovascular disease 1, 2, 3

The American Diabetes Association recommends an HbA1c target of <7% for most patients, with consideration of <6.5% if safely achievable 3
Consider targeting HbA1c <6.5% only in highly selected patients, such as those with short duration of diabetes, managed with lifestyle modifications or metformin only, long life expectancy, absence of significant cardiovascular disease, and no history of severe hypoglycemia 2, 3

Targeting HbA1c below 7% increases risk for death, weight gain, and hypoglycemia in many patients, particularly those with established disease or comorbidities 2, 3
Do not delay treatment intensification if HbA1c remains ≥7.5% (58 mmol/mol) after 3 months of optimized monotherapy 1
Involve patients in target-setting decisions and adjust goals if efforts to achieve targets impair quality of life or cause adverse effects 1, 3, 4, 5

Monitor HbA1c at least twice yearly for patients meeting treatment goals with stable glycemic control 2, 3
Monitor HbA1c quarterly for patients whose therapy has changed or who are not meeting glycemic goals 2, 3